Point72 Asset Management
MCRB icon

Point72 Asset Management’s Seres Therapeutics MCRB Stock Holding History

Point72 Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-107,500
Closed -$3.01M – 2446
2023
Q4 		$3.01M Sell
107,500
-29,955
-22% -$787K 0.01% 1080
2023
Q3 		$6.54M Buy
137,455
+86,435
+169% +$6.6M 0.02% 799
2023
Q2 		$4.89M Buy
51,020
+36,380
+248% +$3.96M 0.01% 822
2023
Q1 		$1.66M Sell
14,640
-20,340
-58% -$2.2M 0.01% 1014
2022
Q4 		$3.92M Sell
34,980
-11,991
-26% -$1.61M 0.01% 810
2022
Q3 		$6.03M Buy
46,971
+30,221
+180% +$3.1M 0.02% 658
2022
Q2 		$1.15M Buy
+16,750
New +$1.44M ﹤0.01% 1044
2021
Q2 		– Sell
-48,734
Closed -$20.1M – 1088
2021
Q1 		$20.1M Buy
48,734
+43,462
+824% +$20M 0.09% 262
2020
Q4 		$2.58M Sell
5,272
-3,047
-37% -$1.78M 0.01% 696
2020
Q3 		$4.71M Buy
+8,319
New +$2.77M 0.02% 577

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Point72 Asset Management's MCRB Position: Q1 2024 in Review

Point72 Asset Management sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 107,500 shares — an estimated $3.01M sold.

Point72 Asset Management first reported a position in MCRB in Q3 2020 and held it in 10 quarters. The position peaked at $20.1M in Q1 2021. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

  • Point72 Asset Management reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Asset Management sold 107,500 Seres Therapeutics shares in Q1 2024, an estimated $3.01M.
  • Point72 Asset Management first reported a position in Seres Therapeutics in Q3 2020 and held it in 10 quarters.
  • Point72 Asset Management's Seres Therapeutics position peaked at $20.1M in Q1 2021.
  • 99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.